CEO: Beth Hoffman

Visit Website

Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modification in neurodegenerative diseases such as Huntington’s Disease. They are pioneering the next-generation of small molecules targeting disease-causing proteins.